RxDoctor Payments Data

Charles Welden, MD

Internal Medicine · Charleston, SCNPI 1578950705

Payments from drug & device makers

$6,653in general payments, 2019–2025

Across 392 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$847
  • Johnson & Johnson$840
  • Bristol Myers Squibb$296
  • Sanofi$261
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,54598%
  • Education$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,653 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$80,962
Medicare patients
308
Services billed
826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$163,477
CreonLipase/Protease/Amylase50$156,857
LinzessLinaclotide67$81,944
Cimzia (2 Pack)Certolizumab Pegol12$79,633
XifaxanRifaximin19$65,951
RelistorMethylnaltrexone Bromide12$27,662
SutabSod Sulf/Pot Chloride/Mag Sulf134$21,436
TrulancePlecanatide19$9,806
MovantikNaloxegol Oxalate21$9,340
DexilantDexlansoprazole17$8,105
Esomeprazole Magnesium57$6,538
Mesalamine21$5,689
Budesonide DrBudesonide34$4,559
Lubiprostone15$4,445
Colestipol Hcl68$3,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,401$238,801117 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance$1,191$103,41950 claims
Braintree Laboratories, Inc.Sutab$44$21,436134 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$847$8,10517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →